Thalassemia  >>  HQK 1001  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HQK 1001 / Viracta Therap
NCT01609595: Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand

Completed
2
10
RoW
sodium 2,2 dimethylbutyrate, HQK-1001, ST20
Boston University, Mahidol University
Beta Thalassemia Intermedia
11/12
12/12
LB-04-THAL, NCT01642758: Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon

Completed
2
10
RoW
Sodium 2,2 dimethylbutyrate, ST20
Boston University, HemaQuest Pharmaceuticals Inc.
Beta Thalassemia Intermedia
11/12
01/13
NCT00790127: Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

Completed
1/2
21
RoW
HQK-1001, Placebo
HemaQuest Pharmaceuticals Inc.
Beta Thalassemia
05/10
05/10

Download Options